Neurocrine Biosciences' Crinecerfont Receives Priority Review for CAH Treatment: FDA Decision Expected by Year-End
Portfolio Pulse from Benzinga Newsdesk
Neurocrine Biosciences' Crinecerfont has received Priority Review from the FDA for the treatment of classic congenital adrenal hyperplasia (CAH). The FDA decision is expected by the end of 2024. If approved, Crinecerfont would be the first new treatment for CAH in 70 years and a first-in-class therapy.
July 01, 2024 | 11:37 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Neurocrine Biosciences' Crinecerfont has received FDA Priority Review for treating classic congenital adrenal hyperplasia (CAH). The FDA decision is expected by the end of 2024. If approved, Crinecerfont would be the first new treatment for CAH in 70 years and a first-in-class therapy.
The FDA's Priority Review designation for Crinecerfont indicates a high likelihood of approval, which would be a significant milestone for Neurocrine Biosciences. This could lead to a substantial increase in the company's stock price due to the potential market impact of the first new CAH treatment in 70 years.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100